Efficacy and Safety of Mometasone Furoate for Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids (ICS) (Study P06115)
Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: SCH 32088 mometasone furoate (MF) metered-dose inhaler (Drug); Placebo metered-dose inhaler BID (Drug)
Phase: Phase 3
Status: Withdrawn
Sponsored by: Merck Sharp & Dohme Corp.
Summary
Mometasone furoate (MF) is a synthetic glucocorticosteroid that, when administered to asthma
patients with a dry powder inhaler (Asmanex® Twisthaler®) at dosages of 100 to 400 mcg twice
daily, has been shown to improve lung function, reduce symptoms of asthma, and reduce
frequency and severity of exacerbations by reducing airway inflammation, with a relatively
low potential to cause systemic side effects such as hypothalamic-pituitary-adrenal (HPA)
axis suppression.
An experimental formulation of MF 100 mcg delivered twice daily via a pressurized
metered-dose inhaler (MDI) also has been shown to be effective in improving lung function of
asthma patients as measured by forced expiratory volume in 1 second (FEV1). This trial is
designed to verify the effectiveness of twice daily MF MDI 100 mcg in treating asthma in
adults and adolescents previously treated with low dosages of inhaled corticosteroids (ICS),
as measured by improvement in morning FEV1 and time to first asthma exacerbation over 12
weeks of treatment.
Clinical Details
Official title: A 12-Week Placebo-Controlled Efficacy and Safety Study of Mometasone Furoate Monotherapy in Subjects With Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Change from Baseline to Endpoint in the morning (AM trough) forced expiratory volume in 1 second (FEV1)
Secondary outcome: Time to first severe asthma exacerbation during the 12 week Treatment Period
Eligibility
Minimum age: 12 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- An adult or adolescent subject with a diagnosis of persistent asthma of >=6 months
duration may be selected for this study.
- Both subject (and/or parent/guardian, if appropriate) and investigator must agree
that changing therapy is acceptable and poses no inherent risk.
- Subject must have been using a low daily maintenance dose of inhaled corticosteroids
(ICS), with or without added long-acting β2-agonist (LABA), for >=12 weeks prior to
Screening, and must have been on a stable regimen (daily dose unchanged) for at least
the last 2 weeks of that period.
- At Screening, the subject must have a prebronchodilator FEV1 between 60% and 90% of
the predicted value when restricted medications have been withheld.
- To be randomized, the subjects must be symptomatic with FEV1 at Baseline must be
between 50% and 85% of predicted.
Exclusion Criteria:
- A subject must not have been admitted to the hospital for management of airway
obstruction within the last 3 months prior to Screening, and must not have
experienced an occurrence of any clinical deterioration of asthma that resulted in
emergency treatment, hospitalization due to asthma, or treatment with additional,
excluded asthma medication, as judged by the clinical investigator at any time from
Screening to Baseline/Randomization.
- In addition, a subject must not have demonstrated a decrease in absolute FEV1 of >20%
at any time from Screening to Baseline, or a decrease in AM peak expiratory flow
(PEF) below the PEF stability limit on any 2 consecutive days prior to
Baseline/Randomization.
Locations and Contacts
Additional Information
Starting date: June 2012
Last updated: May 28, 2015
|